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Abstract
Background: Despite the good prognosis of erythema migrans (EM), some patients have persisting symptoms of various
character and duration post-treatment. Several factors may affect the clinical outcome of EM, e.g. the early interaction
between Borrelia (B.) burgdorferi and the host immune response, the B. burgdorferi genotype, antibiotic treatment as well as
other clinical circumstances. Our study was designed to determine whether early cytokine expression in the skin and in
peripheral blood in patients with EM is associated with the clinical outcome.
Methods: A prospective follow-up study of 109 patients with EM was conducted at the A ˚land Islands, Finland. Symptoms
were evaluated at 3, 6, 12 and 24 months post-treatment. Skin biopsies from the EM and healthy skin were
immunohistochemically analysed for expression of interleukin (IL)-4, IL-10, IL-12p70 and interferon (IFN)-c, as well as for B.
burgdorferi DNA. Blood samples were analysed for B. burgdorferi antibodies, allergic predisposition and levels of systemic
cytokines.
Findings: None of the patients developed late manifestations of Lyme borreliosis. However, at the 6-month follow-up, 7 of
88 patients reported persisting symptoms of diverse character. Compared to asymptomatic patients, these 7 patients
showed decreased expression of the Th1-associated cytokine IFN-c in the EM biopsies (p=0.003). B. afzelii DNA was found in
48%, B. garinii in 15% and B. burgdorferi sensu stricto in 1% of the EM biopsies, and species distribution was the same in
patients with and without post-treatment symptoms. The two groups did not differ regarding baseline patient
characteristics, B. burgdorferi antibodies, allergic predisposition or systemic cytokine levels.
Conclusion: Patients with persisting symptoms following an EM show a decreased Th1-type inflammatory response in
infected skin early during the infection, which might reflect a dysregulation of the early immune response. This finding
supports the importance of an early, local Th1-type response for optimal resolution of LB.
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Introduction
Following a bite by a tick infected with Borrelia (B.) burgdorferi, the
innate immune system is the first line of defense to encounter the
spirochetes. This initial event is likely to determine the magnitude
and quality of both the innate and the ensuing adaptive response
[1]. Erythema migrans (EM) is by far the most common symptom
of Lyme borreliosis (LB) worldwide [2–4]. In general, the
prognosis of antibiotic-treated EM is good [5–7]. However, some
patients are troubled by persisting symptoms of various duration
and character post-treatment [7,8]. Follow-up studies on adult
patients with disseminated infection, i.e. neuroborreliosis (NB),
indicate that as many as 50% of the patients suffer from persisting
complaints after antibiotic treatment [9–12].
The reasons for differences in the clinical outcome of LB are
probably multi-factorial, albeit, largely unknown. To date, there is
no convincing evidence that symptoms post-treatment would be
caused by a persisting infection [13–15]. On the contrary, the
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response to B. burgdorferi, i.e. a weak initial inflammatory response,
not generating proper down-regulatory feedback mechanisms.
Indeed, previous investigations in both mice [16,17] and humans
[18–21] have indicated that a successful clinical outcome requires
an effective inflammatory T helper cell (Th) 1-type response that is
adequately balanced by an anti-inflammatory and Th2-like
response against B. burgdorferi.
Previous studies have shown a predominant Th1-type inflam-
matory response in the skin of EM lesions [1,22]. Furthermore,
analysis of cytokine mRNA in EM skin biopsies from patients
without concomitant EM-associated symptoms, have shown
expression of both IFN-c and IL-10, whereas cytokine analysis
in skin of EM-patients with such symptoms have additionally
shown a large number of macrophage-derived pro-inflammatory
cytokines, such as TNF-a, IL-1b and IL-6 [23]. This indicates that
cytokine expression patterns in the skin may be of importance for
the development of symptoms. However, very little is known about
the clinical outcome of EM in relation to early cytokine expression
in situ in infected skin, which constitutes the primary entrance
route of the spirochetes.
Our aim was to ascertain whether differences in early local
cytokine responses are associated with the clinical outcome of EM.
Therefore, we analysed cytokine expression in vivo in human EM-
skin biopsies in relation to clinical follow-up data. We also
investigated other factors that might influence the outcome,
including the genotype of the infecting B. burgdorferi species and
allergic predisposition in the host.
Results
All patients, except one, completed the antibiotic treatment
without disruption. This patient, who was asymptomatic at all
follow-up time points, discontinued the treatment after seven days,
due to a suspected allergic reaction.
Eighteen of the 109 patients originally included in the study
were excluded due to missing data from the 6-month follow-up.
Ten of the remaining 91 reported persisting symptoms at the 6-
month follow-up; three of those were excluded due to presence of
symptoms .3 weeks before inclusion, resulting in a total of 88
patients (55 women, 33 men, median age 57 years), seven (8%) of
whom reported persisting symptoms 6 months post-treatment.
The symptoms included: arthralgia in knee (2/7), elbow (2/7),
wrist (1/7), ankle (1/7), fatigue (1/7), back pain (1/7) and
hypoesthesia in the skin close to the previous site of the EM (1/7),
whereof five still had symptoms at the 12 month follow-up and
three 24 months post-treatment. However, none of them were re-
treated with antibiotics due to the persisting symptoms. Besides
one patient receiving doxycycline, all symptomatic patients were
treated with a completed course of amoxicillin and none reported
diseases or medication, which might have an impact on the
immune system. No signs of disseminated infection, i.e. arthritis,
NB or acrodermatitis chronicum atrophicans were observed
during the study period. At the time of inclusion, the median
duration of EM was 6 days (range 0–215 days). Three patients had
multiple EM, whereof none had symptoms at the 6-month follow-
up. Fifty-eight patients (66%) had observed a preceding tick-bite.
No statistically significant differences in clinical characteristics, B.
burgdorferi serology or allergic trait were found between the
symptomatic and asymptomatic patients (Table 1).
The expression of IFN-c was decreased in EM biopsies from
symptomatic compared to asymptomatic patients (p=0.003,
Figure 1 B). In addition, the symptomatic patients showed a
strong tendency for decreased expression of IL-12p70 in the EM
lesions compared to the asymptomatic patients (p=0.013, figure 1
A). The expression of IFN-c was correlated with IL-12p70 in both
EM and control biopsies (p#0.01 for both, rho=0.687 and
rho=0.771, respectively). The two patient groups did not differ
regarding expression of IL-4 and IL-10 either in EM (Figure 1 C,
D) or control biopsies (Figure 1 G, H). Neither did the expression
of IL-12p70 and IFN-c in unaffected skin differ between the two
patient groups. The cytokine expressions did not differ between
EM and unaffected skin (data not shown).
Determination of systemic cytokine levels were not carried out
on the 12- and 24-month blood samples, because samples were
missing in many patients. No statistically significant differences in
cytokine levels in either plasma or serum or correlations of
systemic cytokine levels with cytokine expression in skin biopsies
were found between the two groups at any of the three points (at
inclusion, at three or six months post-treatment) (Table 2).
Seventy-five (81.5%) of the 92 EM biopsies, which were
initially screened, were B. burgdorferi DNA positive (Table 3).
Sequencing of the amplicons (n=75) revealed 36 (48%) B. afzelii,
11 (15%) B. garinii and one (1%) B. burgdorferi sensu stricto (s.s.). In
the initial screening of 87 control biopsies from unaffected skin,
20 (23%) were found to contain B. burgdorferi DNA. However,
these findings could not be confirmed by subsequent sequencing.
No differences in detection rates of B. afzelii or B. garinii DNA
were observed between the symptomatic and asymptomatic
patients (Table 3).
Discussion
We found that the local expression of the Th1-type cytokine
IFN-c was decreased in EM lesions from patients with persisting
symptoms 6 months post-treatment in comparison with patients
with no symptoms. In addition, a tendency for decreased
expression of IL-12p70 was found in EM lesions from patients
with persisting symptoms in comparison with asymptomatic
patients. Furthermore, this finding is in line with the observed
correlation between the expression of IFN-c and IL-12p70, since
IL-12p70 induces and maintains IFN-c secretion, which validates
the findings. Surprisingly, no differences in cytokine expression
between the EM and unaffected control biopsies were found.
These results support the hypothesis that a strong Th1-type
response is required early in the course of infection to ensure a
favorable outcome of LB. Our results are the first to show a
possible association between clinical outcome and early, local
cytokine expression in the skin at the site of EM.
The hypothesis that a strong, rapid Th1-type response is
essential for a positive outcome of LB originates from the demand
of a fine-tuned regulation of the immune system for establishment
of an optimal immune response to a pathogen. A powerful, correct
immune activation must be established early in the course of an
infection and later, on a proper moment, needs to be down-
regulated, in order to avoid chronic inflammation and subsequent
tissue damage. A down-regulation, by secretion of immunosup-
pressive cytokines, will appear as a feed-back mechanism, provided
that the initial immune response is strong enough [24].
Regarding LB, the importance of this regulation has previously
been shown in experimental B. burgdorferi infection in mice by
Bockenstedt’s group [17]. Mice, that failed to eradicate the
spirochetes, and developed clinical signs of infection (arthritis),
showed weak Th1-type responses initially in the infection, with
consequent lack of cytokine down-regulation and a gradual
increase in the Th1-response instead. In contrast, resistant mice,
who did eradicate the spirochetes without showing any clinical
signs of infection, showed initially strong Th1-responses, that were
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man, the situation is more complex, since patients are treated with
antibiotics, which most likely eradicate the spirochetes and
modulate the immune response. Our hypothesis is that an early
and strong Th1-response, besides providing an effective eradica-
tion, which is important in order to avoid dissemination before
antibiotic treatment, is a prerequisite for a proper down regulation
of the inflammation, thus avoiding low grade chronic inflamma-
tion that may cause persistent symptoms despite absence of the
spirochetes. This hypothesis is corroborated by research findings
regarding cytokine patterns in blood [20,25] and in the target sites
of disseminated LB, i.e. the cerebrospinal [26–28] and synovial
[29,30] fluids.
Overall, the long-term clinical outcome after treatment of EM
was good, which agrees with earlier observations [31–34]. Indeed,
among the seven patients with residual symptoms at the 6-month
follow-up, all but three had recovered at the 2-year follow-up. The
symptoms reported by the patients 6 months post-treatment are
also known to occur in the general population [35] and have in
addition been observed after other acute illnesses, such as Epstein-
Barr virus infection [36].
One of the symptomatic patients had a very long EM duration
(215 days). Skin lesions with long duration is, however, not
uncommon in European EM, which are more commonly caused
by B. afzelii and characterized by slowly expanding skin lesions and
less associated symptoms at diagnosis compared to North
American EM [23,37]. This particular EM measured 30 cm in
diameter and had a characteristic appearance. She presented with
fatigue and arthralgia at baseline and gradually developed
arthralgia in the elbow, without clinical signs of disseminated
disease. The symptoms had disappeared spontaneously at the 24
month follow-up. B. burgdorferi serology was positive at baseline and
at the follow-ups. Interestingly, the PCR assay was negative, which
could be due to a spontaneous eradication of the spirochetes prior
to treatment or a low density of spirochetes in the large
erythematous area.
Allergic predisposition was assessed, because it has been shown
that experimental Th2-deviation in mice leads to a less favorable
outcome of LB [16]. However, we found no differences in allergic
traits between symptomatic and asymptomatic patients. Further-
more, neither the development of symptoms, nor the disparities in
Th1-type cytokine expression in EM-biopsies could be coupled to
infection with different B. burgdorferi species, since the two patient
groups did not differ with respect to the presence of B. afzelii or B.
garinii infection. B. afzelii was the most common genotype found in
this study, detected in 48% of the EM-biopsies, which concurs
with previous European studies [38,39]. In 18.5% of the EM
biopsies, no B. burgdorferi DNA was detected.
Table 1. Clinical characteristics of the included patients.
Variable
Patients with
symptoms at 6 mos
Included in IHC (A)
Patients with no
symptoms at 6
mos (B)
Statistical
comparison
(A vs B)
Patients with no
symptoms at 6 mos
Included in IHC (C)
Statistical
comparison
(A vs C) In total (A+B)
N 78 1 1 8 8 8
Sex F/M 5/2 50/31 NS 11/7 NS 55/33
Age (years) range 30–68 23–88 23–73 23–88
Age (years) median 55 58 NS 49 NS 57
Single/Multiple EM 7/0 78/3 NS 16/2 NS 85/3
Tick bite reported Y/N 3/4 55/25 NS 14/4 NS 58/29
EM size (cm) range 5–30 3–37 5–16 3–37
EM size (cm) median 15 10 NS 9 NS 10
Borrelia antibodies
pos/n analysed
C6
3 mos 4/7 39/81 NS 9/18 NS 43/88
6 mos 4/7 36/78 NS 7/18 NS 40/85
IgM
3mos 7/7 48/81 NS 11/18 NS 55/88
6mos 6/7 43/78 NS 10/18 NS 49/85
IgG
3mos 5/7 51/81 NS 14/18 NS 56/88
6mos 7/7 46/78 NS 12/18 NS 53/85
Allergy Y/N 1/6 25/56 NS 7/11 NS 26/62
EM duration (days)
*
Range 2–215 0–63 0–45 0–215
Median 46 N S 7 N S 6
*Duration of EM prior to antibiotic treatment.
Clinical characteristics of the included patients, statistical comparison of patients with and without symptoms at 6 months post-treatment, and data on patients who
were asymptomatic at 6 months and were included in the immunohistochemical analysis of in vivo cytokine expression in EM skin biopsies. All patients are included in
the column farthest to the right.
IHC, immunohistochemistry; F, female; M, male; EM, erythema migrans; Y, yes; N, no; pos, positive; Ig, immunoglobulin; NS, not significant.
doi:10.1371/journal.pone.0018220.t001
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expression of IFN-c in the skin cannot be explained by differences
in preparation of the specimens, because all staining and biopsy
management were performed in the same manner, and the
cytokine expressions were analysed randomly and blindly
throughout the study.
The ability to establish Th1 or Th2 responses in mice is known
to depend on the genetic background [17] and similar differences
in humans have been reported [40,41]. The observed differences
between individuals in cytokine expression in the skin may thus be
due to differences in the tendency to preferentially mount Th1
responses based on differences in immune genes. In line with this
and according to our hypothesis that an early strong Th1-response
is beneficial in B. burgdorferi infection, genetic differences may
possibly also explain the different outcomes of EM. In any case,
due to the non-experimental design of this study, the results must
be interpreted with caution. However, since the two groups
showed no differences in confounding factors, such as clinical or
EM characteristics, the decreased expression of Th1-type
cytokines in the EM biopsies from patients with persisting
symptoms indicates that the local Th1-type response itself may
contribute to the clinical outcome.
This study has, however, several limitations. We did not include
a control group of patients without LB and the assessment of
symptoms was merely based on questionnaires and phone
interviews, without performing medical examinations or using
validated tests for assessment of symptom severity. Neither was
testing for co-infections with other tick-borne pathogens done. In
addition, several patients were excluded due to lack of compliance
with the follow-ups, which might partly be explained by a
successful outcome in most patients and possibly by logistics in the
isles.
In conclusion, patients with persisting symptoms 6 months after
antibiotic treated EM showed reduced expression of Th1-like
cytokines in the EM lesions prior to antibiotic treatment. This
finding indicate an impact of the initial local immune response on
the long-term outcome of LB and support the hypothesis that an
early and strong Th1-type response is important for optimal
resolution of LB. Additional studies are, however, needed to
further substantiate our findings.
Materials and Methods
Ethics statement
The study was approved by The Regional Ethics Committee at
A ˚land Central Hospital, the A ˚land Islands, Finland, on June 3,
2002. Written, informed consent was obtained from all partici-
pants.
Study design
This prospective follow-up study was carried out from 2002 to
2004 on the A ˚land Islands, Finland, where LB is hyperendemic.
Figure 1. Immunohistochemical detection of cytokine expression in skin biopsies. Erythema migrans (EM) skin lesions and biopsies from
unaffected skin of seven patients with and 18 patients without symptoms 6 months post-treatment. The diagrams illustrate the expression of
interleukin (IL)-12p70 (A), interferon (IFN)-c (B), IL-4 (C), and IL-10 (D) in EM-biopsies and IL-12p70 (E), IFN-c (F), IL-4 (G), and IL-10 (H) in unaffected
skin. Mann-Whitney U-test and a manual Bonferroni correction were used for statistical analyses and p#0.0125 was considered significant.
doi:10.1371/journal.pone.0018220.g001
Table 2. Systemic cytokine levels estimated by detection in multiple bead assays.
Time point Cytokine
No. of
samples with
cytokine
detectable
a
Median
(pg/ml)
Range
(pg/ml) Time point Cytokine
No. of
samples with
cytokine
detectable
a
Median
(pg/ml)
Range
(pg/ml)
Statistical
analysis
Patients with no symptoms at 6 months (n=80) Patients with symptoms at 6 months (n=7)
Inclusion
serum
IL–4 44/80 0.32 0.065–42 Inclusion
serum
IL–4 6/7 1.2 0.32–40.6 NS
IL–10 76/80 7.72 0.32–180 IL–10 7/7 5.015 0.64–131 NS
IL–12p70 27/80 0.32 0.065–1068.8 IL–12p70 5/7 1.43 0.32–21.59 NS
IFN–c 33/80 0.32 0.32–115.4 IFN–c 3/7 0.32 0.32–12.74 NS
Patients with no symptoms at 6 months (n=60) Patients with symptoms at 6 months (n=5)
b
3 months
plasma
IL–4 55/60 6.1 0.065–69.35 3 months
plasma
IL–4 4/5 9.63 0.32–22.5 NS
IL–10 59/60 13.44 0.065–1221.4 IL–10 5/5 20.4 8.2–33 NS
IL–12p70 34/60 0.36 0.065–1693 IL–12p70 4/5 1.98 0.065–16.3 NS
IFN–c 56/60 4.5 0.065–100.4 IFN–c 5/5 2.36 0.64–10.56 NS
6 months
plasma
IL–4 55/60 7.2 0.32–86.5 6 months
plasma
IL–4 2/5 0.32 0.32–9.4 NS
IL–10 60/60 13.13 2.36–1475.45 IL–10 5/5 10.69 2.14–16.88 NS
IL–12p70 25/60 0.32 0.065–44 IL–12p70 2/5 0.065 0.065–8.52 NS
IFN–c 57/60 4.58 0.065–48.7 IFN–c 2/5 0.32 0.065–4.87 NS
IL, interleukin; IFN, interferon; NS, not significant.
aSpecified cytokine detectable within the range of the standard curve concentrations; concentrations below the lowest point of the standard curve were considered
undetectable.
bTwo samples missing, hence only 5/7 patients.
doi:10.1371/journal.pone.0018220.t002
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The study comprised 109 patients (72 women, 37 men; mean age
56 years) who had a newly discovered EM and were receiving care
at A ˚land Central Hospital, Finland. Inclusion criteria were age $18
years and presence of an EM, defined as an expanding rash .5c m
in diameter. None of the included patients had received prior
antibiotic treatment for the current EM. The participants
completed a questionnaire with the following information: age,
gender, general health status, other diseases that may have an
influenceonthe immune systemtreatmentwith immunosuppressive
drugs or antibiotics at inclusion or within two months prior to
inclusion,symptomsat baseline,EMlocation and duration,number
and size of the EM-lesions and whether a preceding tick-bite had
been noticed. Patients gave blood samples at baseline and after 3, 6,
12and24monthsandtheyansweredthehealthquestionnaireatthe
same time points, in some cases by telephone. Patients were divided
into two groups at the 6-month follow-up: those with and those
without self-reported symptoms, which had arisen in conjunction
with the EM or afterwards, and could possibly be associated with
the EM. The limit for debut of symptoms was set at ,3 weeks prior
to inclusion. The 6-month evaluation limit was chosen, because by
that time symptoms consistent with both non-infectious complica-
tions and treatment failure with dissemination of the infection
should have appeared. The patients were treated with amoxicillin
(1 g twice daily), or in case of penicillin allergy with doxycycline
(200 mg once daily), for 14 days.
Procedures
B. burgdorferi-specific antibodies were measured in serum at all
follow-up time points. ELISA kits were used to measure IgM and
IgG antibodies against B. burgdorferi flagellum (Dako, Denmark)
and against a mixture of the recombinant B. burgdorferi antigens
p18, p41 internal fragment, p100 and outer surface protein C
(OspC) (recomWell ELISA, Mikrogen, Germany). Both IgM and
IgG antibodies to a synthetic B. burgdorferi C6-peptide were
measured using a QuickELISA C6 Kit (Immunetics, MA, USA),
followed by a Western blot (WB) (RecomBlot, Mikrogen,
Germany) for analysis of IgG antibodies to recombinant B.
burgdorferi antigens.
Allergic propensity was examined at baseline, by measuring
total and allergen-specific IgE antibodies in plasma (Immuno-
CAP
TM, Phadia AB, Sweden), according to the manufacturer’s
instructions. Specific IgE antibodies directed to common food and
inhaled allergens were measured with Phadiatop CombiH (Phadia
AB). A sample was considered positive, if at least one of the
different assays was positive.
Before antibiotic treatment, a 4 mm skin punch biopsy was
taken under local anesthesia (Xylocain 10 mg/ml, AstraZeneca,
Sweden), from the outer edge of the red EM zone and from an
opposite, healthy body site (control). The biopsies were split in two
pieces and immediately snap-frozen in a mixture of isopentane
and liquid CO2 and stored at 270uC. Serial sections (6 mm) were
later obtained using a Leitz CM3050 cryostat (Leica Micro-
systems, Gothenburg, Sweden) and 2–6 sections were placed in
each well of a three-well microscope slide (Novakemi, Stockholm,
Sweden) pre-coated with 0.1% poly-L-lysine (Sigma, Stockholm,
Sweden). These preparations were air-dried and kept at 270uC,
until stained.
Due to the complicated and time-consuming laboratory
procedure, not all biopsies from the asymptomatic patients were
used for immunohistochemical staining. Thus, cytokine expression
was analysed in biopsies from the 7 patients with and 18 (originally
chosen to match for age and sex) without symptoms at the 6-
month follow-up. These patients were considered representative of
the total asymptomatic group (n=81) in terms of reported
symptoms at baseline and at the three month follow-up (data
not shown). The slides were fixed for 5 minutes at 4uCi na n
acetone bath and then dried for 30 min at room temperature
(RT), after which endogenous biotin was blocked using a
streptavidin/biotin blocking kit (Immunkemi AB, Sweden).
Saponin-phosphate buffered saline (PBS, 0.1%; Sigma-Aldrich
AB and Medicago AB, Sweden) was used as washing and dilution
buffer. Before incubation, the slides were washed for 30 min in 5%
normal serum (containing goat, mouse and rat serum, each at 5%;
[code numbers X0907, X0910 and X0912; DakoCytomation,
Denmark]). Antibodies were titrated for maximal fluorescence in
sections of inflamed tonsil [42] and validation of the staining
method was done using isotype antibodies and PBS as negative
controls. The slides were incubated in a humidified chamber for
60 min at RT with the following antibodies: primary mouse anti-
human interferon (IFN)-c monoclonal IgG1 (diluted 1:1000, clone
1-D1K; Mabtech AB, Sweden), mouse anti-human interleukin
(IL)-12p70 monoclonal IgG1 (1:500, clone 24945; R&D Systems,
MN, USA), rat anti-human IL-4 monoclonal IgG1 (1:500, clone
MP4-25D2; BD Biosciences, CA, USA), rat anti-human IL-10
monoclonal IgG2a (1:500, clone JES3-19F1; BD Biosciences) and
isotype mouse-IgG1k antibodies (1:1000 for IFN- c and 1:500 for
IL-12p70, clone MOPC-21; BD Biosciences), rat-IgG1 (1:500,
clone R3-34; BD Biosciences) and rat-IgG2a (1:500, clone R35-95;
BD Biosciences). After washing, the slides were further incubated
for 60 min at RT with secondary antibodies; goat anti-mouse
polyclonal IgG1 conjugated with Cy3 (diluted 1:10 for IFN- c and
1:100 for IL-12p70; Caltag Laboratories, Burlingname, CA, USA)
Table 3. PCR analysis of B. burgdorferi DNA in erythema migrans skin biopsies.
Variable
Patients with
symptoms at 6
mos Included
in IHC (A)
Patients with
no symptoms
at 6 mos (B)
Statistical
comparison
(A vs B)
Patients with no
symptoms at 6
mos Included in
IHC (C)
Statistical
comparison
(A vs C)
All included
in the study
(A+B)
n (patients) 78 1 1 8 8 8
n (EM biopsies) 78 5 2 0 9 2
PCR positive 64 2 1 1 4 8
Subtypes
a B.afzelii/garinii/sensu stricto 5/1/0 31/10/1 NS 6/5/0 NS 36/11/1
Undetectable
a 14 3 9 4 4
aIncludes both PCR positive biopsies in, which B. burgdorferi subtypes were undetectable (n=27), and PCR negative biopsies (n=17).
n, number; EM, erythema migrans; IHC, Immunohistochemistry; B., Borrelia; NS, not significant.
doi:10.1371/journal.pone.0018220.t003
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diluted 1:10 for IL-4 and 1:100 for IL-10; Jackson ImmunoR-
esearch Laboratories Inc., West Grove, PA, USA). After additional
washing, a drop of SlowFadeHAntifade mounting solution
(Molecular Probes, Eugene, OR, USA) was added to each well,
cover glasses were mounted and the slides were stored at +4uC
(maximum 48 h).
The slides were anonymised and all section were blindly
analysed according to a protocol by two of the authors (JS and LF),
using a Nikon Eclipse E600 (and Nikon EZ-C1 software version
3.30, Nikon Instruments Europe, the Netherlands) at excitation
wavelengths of 546 (Cy3) and 488 (FITC) nm. Cytokine expression
was estimated on a scale from 0 to +++; where +, ++ and +++
corresponded to 1–10, 10–20 and .20 cytokine expressing
(positive) cells/section, respectively (Table 4). These estimations
were given numeral values (0=0, +=1, ++=2 and +++=3).
Thus, a semi-quantitative and comparable estimation of the
cytokine expression in the skin specimens was obtained.
The presence of IL-4, IL-10, IL-12p70 and IFN-c in serum
samples obtained at inclusion and plasma samples from the 3- and
6-month follow-ups was determined using a Milliplex
TM MAP
High Sensitivity Human Cytokine kit (HSCYTO-60SK; Millipore
Corporation, Billerica, MA, USA) according to the manufacturer’s
instructions. STarStation v.3.0 (Applied Cytometry, Sheffield,
UK) was used for data acquisition and analysis. Values below the
lowest value of the standard curve were assigned half the values of
the lowest standard point.
One half of each skin biopsy was analysed for the presence of B.
burgdorferi DNA. DNA extraction and quantitative real-time
polymerase chain reaction (PCR) was performed as described by
Comstedt et al. [43]. DNA was extracted using the Puregene DNA
isolation protocol (Gentra Systems, Minneapolis, MN, USA) and
stored at 220uC. DNA extracts were analysed for presence of the
B. burgdorferi complex by a quantitative PCR assay with probes and
primers specific for the 16S rRNA gene. Serially diluted B.
burgdorferi 31 and B. hermsii HS1 DNA were used as standards. B.
burgdorferi species were identified by direct sequencing of the
amplicons generated from the /rrs/(16S)-/rrl/ (23S) intergenic
spacer or 16S gene PCRs. When necessary, nested modification of
these assays was used to increase amplification success. Skin
biopsies (92 EM and 87 control biopsies) were analysed using
quantitative real-time PCR for detection of B. burgdorferi DNA.
Biopsies found to contain B. burgdorferi DNA were analysed by 16S
PCR alone or 16S PCR followed by an OspC-nested PCR. The
biopsies that were positive in the OspC-nested PCR were
sequenced with OspC-primers. 16S primers were used to increase
accuracy if results obtained with the OspC-primers were
uncertain. All negative OspC-nested analyses were sequenced
with 16S-primers.
Statistical analyses
Clinical data and B. burgdorferi- and allergen antibody responses
were analysed using logistic regression, Fisher’s exact test or
Mann-Whitney U-test for comparison of the two groups (ie.
patients with and without symptoms at the 6-month follow-up).
Mann-Whitney U test was used to compare the two groups
regarding cytokine expression in skin biopsies and cytokine levels
in serum and plasma. After Mann-Whitney, manual Bonferroni
correction was performed to correct for the four cytokine
variables. Wilcoxon signed rank test was used to compare the
cytokine expression in EM lesions with the corresponding
expression in unaffected skin. Fisher’s exact test was applied to
serum and plasma data, since they included many values below the
detection level and additionally for analysis of the distribution of
detectable DNA of different B. burgdorferi subspecies. Spearman’s
rank correlation test was used to assess associations between
cytokine expression in the skin biopsies and blood samples.
Statistical analyses were performed using PASW Statistics 18
software for Microsoft (SPSS Inc., Chicago, IL, USA) and
GraphPad Prism version 5.02 for Microsoft (GraphPad Software
Inc, San Diego, CA, USA). A p-value#0.05 was considered
significant, whereas a p-value#0.0125 was considered significant
after correction for multiple variables.
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